Oryzon Genomics (MC:ORY) CEO Carlos Buesa sat down with Proactive at the BIO CEO & Investor Conference in New York. The Barcelona, Spain-based company's CEO says he is anticipating a 'defining year' in upcoming clinical data, as well as pursuing a dual listing on the Nasdaq in New York.
0 Yorumlar